TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00063570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 14 days, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days, until disease progression
Study: NCT04123236

Intervention type: OTHER
Intervention: Age 0-18
Description: Patients under 18 years of age

Intervention type: OTHER
Intervention: Age 0-18
Description: Patients under 18 years of age

Intervention type: OTHER
Intervention: Age 0-18
Description: Patients under 18 years of age

Intervention type: OTHER
Intervention: Age 0-18
Description: Patients under 18 years of age

Intervention type: OTHER
Intervention: Age 18-26
Description: Patients over18 years of age

Intervention type: OTHER
Intervention: Age 18-26
Description: Patients over18 years of age

Intervention type: OTHER
Intervention: Age 18-26
Description: Patients over18 years of age

Intervention type: OTHER
Intervention: Age 18-26
Description: Patients over18 years of age

Intervention type: OTHER
Intervention: Girls
Description: Girls

Intervention type: OTHER
Intervention: Girls
Description: Girls

Intervention type: OTHER
Intervention: Girls
Description: Girls

Intervention type: OTHER
Intervention: Girls
Description: Girls

Intervention type: OTHER
Intervention: Boys
Description: Boys

Intervention type: OTHER
Intervention: Boys
Description: Boys

Intervention type: OTHER
Intervention: Boys
Description: Boys

Intervention type: OTHER
Intervention: Boys
Description: Boys
Study: NCT04474665

Intervention type: DEVICE
Group type: OTHER
Intervention: Reverse shoulder arthroplasty utilizing Blueprint Software
Description: Reverse shoulder arthroplasty utilizing Blueprint Software
Study: NCT04879667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy
Description: we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
Study: NCT01304095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
Study: NCT03223870

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Diagnostic
Study: NCT03057613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks for 16 weeks given by IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT 60-66Gy
Description: 60-66Gy for 6 weeks
Study: NCT03555513

Intervention type: PROCEDURE
Intervention: living kidney transplantation
Description: receiving kidney transplantation from living donor
Study: NCT03337360

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impryl
Description: Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients, placebo
Study: NCT02341638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT01439672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meal and insulin challenge
Description: The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \~100mg/dl at 1100.
Study: NCT00791505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin
Description: 1500 mg a day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Description: 2000 mg a day for 10 days
Study: NCT02103387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Training
Description: Cognitive Behavioral Training \[CBT\] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Relaxation Training \[RT\] (muscle relaxation, deep breathing, guided imagery, meditation)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
Study: NCT01470521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hookworm larvae
Description: Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
Study: NCT02601248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theliatinib
Description: Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
Study: NCT04942821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin and coronally advanced flap
Description: CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft and coronally advanced flap
Description: Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
Study: NCT01650025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 active probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 placebo
Study: NCT01342484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: comparison of different dosages of drug (low vs high) vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1356 low dose
Description: comparison of different dosages of drug (low vs high) vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1356 high dose
Description: comparison of different dosages of drug (low vs high) vs placebo
Study: NCT00649259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride ER Tablets 10 mg
Description: 2x10mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 10 mg
Description: 2x10mg, single dose fed
Study: NCT04296214

Intervention type: DRUG
Intervention: 5-azacitidine
Description: Cycles of 28 days

Intervention type: DRUG
Intervention: 5-azacitidine
Description: Cycles of 28 days
Study: NCT05410444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clean Intermittent Catheterization
Description: Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling catheterization
Description: A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
Study: NCT01886339

Intervention type: OTHER
Intervention: SNIF test (Sniff Nasal Inspiratory Force)
Study: NCT01733979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heme-Iron Polypeptide
Description: Heme-Iron Polypeptide (1g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Heme-Iron
Description: Heme-Iron (1g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Organic Iron
Description: Organic Iron (1g/day)
Study: NCT00871845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary and Lifestyle modification educational sessions
Description: 6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
Study: NCT03939845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: external- beam radiotherapy (EBRT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: transarterial chemoembolization (TACE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)
Study: NCT02329080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomial cytarabine
Description: Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiotherapy
Description: whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
Study: NCT01119742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine Hydrochloride 1%
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine Hydrochloride 1% B
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butenafine Hydrochloride 1%
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle A
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle B
Description: Twice daily application for 7 days
Study: NCT01767675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Cytoreductive Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Cytoreductive Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platinum-based systemic chemotherapy postoperatively
Description: 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platinum-based systemic chemotherapy postoperatively
Description: 6 cycles
Study: NCT00923403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant sterol enriched soymilk
Description: plant sterol enriched soymilk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control dairy milk
Description: control dairy milk
Study: NCT01824511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smokers cease smoking
Description: Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
Study: NCT04518215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plain Block
Description: Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Venous Analgesia
Description: Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Venous Analgesia
Description: Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.
Study: NCT00993265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
Study: NCT00833950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase Out treatment in pure tone tinnitus patients
Description: Phase Out treatment: 30 min 3x/w during 6 weeks
Study: NCT02458521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
Study: NCT04825795

Intervention type: DRUG
Intervention: DPP4-inhibitor
Description: Prescription of DPP4-inhibitor during the period between the two coronary CT scan

Intervention type: DRUG
Intervention: No DPP4-inhibitor
Description: No prescription of DPP4-inhibitor during the period between the two coronary CT scan
Study: NCT04391036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Eudragit® Content Vaginal Film
Description: High (12.8%) Eudragit® Content Vaginal Film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Eudragit® Content Vaginal Film
Description: High (12.8%) Eudragit® Content Vaginal Film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Eudragit® Content Vaginal Film
Description: Low (6.4%) Eudragit® Content Vaginal Film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Eudragit® Content Vaginal Film
Description: Low (6.4%) Eudragit® Content Vaginal Film
Study: NCT02479100

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast Enhanced Spectral Mammogram
Description: Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
Study: NCT05798676

Intervention type: OTHER
Intervention: overweight/obesity
Description: the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
Study: NCT03363750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind-body-skills group
Description: mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
Study: NCT03598816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: -Tremelimumab will be administered first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: -Tremelimumab will be administered first

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM v1.0 System
Description: -Integrated electroporation device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA Vaccine
Description: -At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1